Argon Medical Deviceshttp://www.argonmedical.com
Argon Medical DevicesThu, 12 Mar 2015 21:57:13 +0000en-UShourly1http://wordpress.org/?v=4.1.1Argon Medical’s CLEANER XT™ and CLEANER 15™ Rotational Thrombectomy Systems Receive FDA Clearance for Mechanical Declotting and Infusion in the Peripheral Vasculaturehttp://www.argonmedical.com/argon-medicals-cleaner-xt-and-cleaner-15-rotational-thrombectomy-systems-receive-fda-clearance-for-mechanical-declotting-and-infusion-in-the-peripheral-vasculature/
http://www.argonmedical.com/argon-medicals-cleaner-xt-and-cleaner-15-rotational-thrombectomy-systems-receive-fda-clearance-for-mechanical-declotting-and-infusion-in-the-peripheral-vasculature/#commentsWed, 19 Nov 2014 12:00:59 +0000http://www.argonmedical.com/?p=12206PLANO, Texas, Nov. 19, 2014 /PRNewswire/ – Argon Medical Devices, Inc. announced today that the company has received clearance from the US Food and Drug Administration to begin marketing the CLEANER XT™ and CLEANER 15™ Rotational Thrombectomy Systems for mechanical declotting and controlled and selective infusion of physician-specified fluids, including thrombolytics, in the peripheral vasculature. This new clearance enables physicians to apply CLEANER’s capability for cleaning wall-adherent thrombus to the peripheral vasculature when an IVC filter is present. This indication augments Cleaner’s existing clearance for mechanical declotting of native vessel dialysis fistulae and synthetic dialysis access grafts. Venous thromboembolism (VTE) is the third most prevalent cardiovascular illness following acute coronary syndrome and stroke1, and it is estimated that there are approximately 1 million cases in the US each year2.

The CLEANER Rotational Thrombectomy System is immediately available for use in the peripheral vasculature, and Argon is formally launching the new indication at the 27th Annual International Symposium of Endovascular Therapy, to be held at the Diplomat Hotel in Hollywood, FL from January 31st to February 4th, 2015.

“Safely expanding the application of the CLEANER family of products to the peripheral vasculature means more effective therapy for patients suffering from peripheral thrombosis and occlusions,” stated George Leondis, President of Argon Medical Devices. “Combining an atraumatic approach with efficient thrombus removal is unique among thrombectomy devices, and we are excited to make this product available for a wider range of applications.”

The CLEANER family of Rotational Thrombectomy Systems is available from Argon Medical Devices, and is designed by Rex Medical, LP. With the FDA’s clearance of this new indication, patients requiring treatment of thrombus in the peripheral vasculature will have access to advanced therapy with the CLEANER family of devices.

About RoundTable Healthcare Partners RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the health-care industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified health-care companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

About Rex Medical, LP Rex Medical, LP, based in Conshohocken, PA, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery and oncology markets. Rex Medical is ISO 13485 certified.

]]>http://www.argonmedical.com/argon-medicals-cleaner-xt-and-cleaner-15-rotational-thrombectomy-systems-receive-fda-clearance-for-mechanical-declotting-and-infusion-in-the-peripheral-vasculature/feed/0Argon Medical Devices, Inc. Acquires US Biopsy and the TLAB® Transjugular Liver Biopsy Instrumenthttp://www.argonmedical.com/argon-medical-devices-inc-acquires-us-biopsy-and-the-tlab-transjugular-liver-biopsy-instrument/
http://www.argonmedical.com/argon-medical-devices-inc-acquires-us-biopsy-and-the-tlab-transjugular-liver-biopsy-instrument/#commentsTue, 09 Sep 2014 17:01:14 +0000http://www.argonmedical.com/?p=11926PLANO, Texas, September 9, 2014 /PRNewswire/ — Argon Medical Devices, Inc. announced today that it has acquired Promex Technologies, LLC (d/b/a US Biopsy), a manufacturer of soft-tissue biopsy products including the TLAB® Transjugular Liver Biopsy Instrument (“TLAB”). The acquisition establishes Argon Medical as one of two companies competing in the transjugular liver biopsy market and completes its line of soft-tissue biopsy instruments. Argon Medical is a leading biopsy device manufacturer and the only company to offer a full-core biopsy instrument commonly used in percutaneous liver biopsies. With the addition of TLAB, Argon Medical now offers devices to collect liver samples using either percutaneous or transjugular access approaches.

“US Biopsy has been active in the transjugular liver biopsy market since the procedure was first pioneered in the 1990s. This unique experience was integral in designing TLAB with differentiated features that improve upon existing technologies,” said Argon Medical’s President, George Leondis. “This acquisition allows us to leverage our current soft tissue biopsy portfolio and further demonstrates our commitment to growth in the Interventional space.”

TLAB is designed with patented Flexcore® technology that allows the needle to flex to acute angles and still function consistently. This unmatched flexibility is essential in transjugular liver biopsy where the needle must bend to enter the hepatic vein coming from the liver and collect a specimen via the vessel wall. Patients who require a liver biopsy using this approach have, or are suspected to have, liver disease, which often causes the liver to harden over time making it more difficult to access. TLAB’s Flexcore® technology and sharp Tru-Track™ trocar needle tip allow the needle to enter tough liver tissue without diving or deviating from the track.

According to the American Liver Foundation, 1 in 10 Americans suffer from liver disease and the prevalence of liver diseases such as hepatitis C, non-alcoholic fatty liver disease, and liver cancer are on the rise. Additionally, up to 25% of Americans may have non-alcoholic fatty liver disease. These patients may require a liver biopsy for an accurate diagnosis and those patients who have abnormal blood coagulation or patients with a build-up of fluid in the abdomen (ascites) will likely require a transjugular liver biopsy.

RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified healthcare companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

]]>http://www.argonmedical.com/argon-medical-devices-inc-acquires-us-biopsy-and-the-tlab-transjugular-liver-biopsy-instrument/feed/0CLEANERXT™ Rotational Thrombectomy System Launched in the UShttp://www.argonmedical.com/cleanerxt-rotational-thrombectomy-system-launched-in-the-us/
http://www.argonmedical.com/cleanerxt-rotational-thrombectomy-system-launched-in-the-us/#commentsTue, 06 May 2014 19:02:12 +0000http://www.argonmedical.com/?p=10792PLANO, Texas, May 6, 2014 /PRNewswire/ — Argon Medical Devices, Inc. announced today that the company has begun marketing the CLEANERXT™ Rotational Thrombectomy System as a new addition to the CLEANER family of dialysis products. With increased power and torque for cleaning wall-adherent thrombus, and the ability to be introduced through a 6 Fr sheath, CLEANERXT combines torque with trackability. Its innovative sinusoidal wire design is radiopaque and conforms to varying lumen diameters, actively cleaning wall-adherent thrombus.

Argon introduced the CLEANERXT Rotational Thrombectomy System at the 2014 Society of Interventional Radiology meeting in San Diego.

“We continuously look at ways to improve our product offerings so that physicians can provide safe and effective therapy to their patients,” stated George Leondis, President of Argon Medical Devices. “CLEANERXT provides a tremendous combination of power and minimal invasiveness. Among wall-contacting thrombectomy devices, CLEANERXT provides physicians an unmatched ability to effectively macerate wall-adherent thrombus on a 6 Fr device platform.”

The CLEANERXT Rotational Thrombectomy System was designed by Rex Medical, LP for mechanical declotting of native vessel dialysis fistulae and synthetic dialysis access grafts. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), almost 400,000 patients undergo dialysis each year. With this product launch, patients who require thrombectomy will now have access to a more efficient and effective therapy option.

About RoundTable Healthcare PartnersRoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the health-care industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified health-care companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

About Rex Medical, LPRex Medical, LP, based in Conshohocken, PA, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery and oncology markets. Rex Medical is ISO 13485 certified.

PLANO, Texas, Jan. 16, 2014 /PRNewswire/ – Argon Medical Devices, Inc. announced today that the company has received clearance from the US Food and Drug Administration to begin marketing the Option™ELITE retrievable inferior vena cava (IVC) filter with a new over-the-wire delivery technique. This new clearance enables physicians to safely deliver the filter to a patient’s IVC by following the path of a guidewire. The guidewire assists in keeping the filter centered in the IVC upon placement. The over-the-wire technique is a standard of care in many endovascular procedures and the OptionELITE is the only retrievable IVC filter that can be delivered by passing the filter’s apex over a guidewire.

“Applying the over-the-wire technique to deliver an IVC filter is a significant development, employing a technique we frequently use during endovascular procedures. It gives a physician more control to accurately position the filter during delivery,” said Dr. Munier Nazzal, Chief of Vascular and Endovascular Surgery at the University of Toledo.

Argon is launching the OptionELITE filter with the new over-the-wire delivery technique at the 26th Annual International Symposium of Endovascular Therapy, to be held in Miami Beach, FL from January 18th – 22nd, 2014.

“We remain committed to providing best-in-class products that allow physicians to provide safe and effective therapy to the patients they treat,” stated George Leondis, President of Argon Medical Devices. “Among retrievable IVC filters, finding the right combination of features that make a filter easy to deliver, provide stability in the IVC, and make it easy to retrieve, is a key balance that few designs have achieved. Since its launch in the U.S. market the Option™ELITE has demonstrated that balance and we’re pleased to now offer it to more patients worldwide.”

Argon Medical Devices, Inc. also announced that the company would begin marketing the OptionELITE™ in Europe following the device’s recent approval for the CE Mark. Additionally, the company recently received approval from Health Canada and recently began marketing the product in that geography.

The Option™ELITE retrievable inferior vena cava (IVC) filter was designed by Rex Medical, LP for prevention of recurrent pulmonary embolism (PE). In the United States alone, PE is the third leading cause of death among hospitalized patients. With these approvals and subsequent launches, more patients worldwide who require PE protection now have access to the benefits of the OptionELITE IVC filter.

About RoundTable Healthcare PartnersRoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the health-care industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified health-care companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

About Rex Medical, LPRex Medical, LP, based in Conshohocken, PA, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery and oncology markets. Rex Medical is ISO 13485 certified.

PLANO, Texas, April 4, 2013 /PRNewswire/ — Continuing our commitment to provide best-in-class medical devices for the prevention of recurrent pulmonary embolism (PE), Argon Medical Devices, Inc. takes another step forward with the launch of the Option™ELITE Retrievable Vena Cava Filter. The OptionELITE IVC Filter, designed by Rex Medical, LP, provides the clinician with the same safe and trusted design now enhanced for ease of delivery and retrievability.

“Safety and retrievability are without question two of the most vital, and rare, characteristics in a best-in-class retrievable IVC filter. Argon is pleased to be able to offer the best of these worlds by introducing the OptionELITE,” stated George Leondis, President of Argon Medical Devices. “This technology provides clinicians with a safe and stable IVC filter that can be confidently deployed and retrieved while minimizing the risk of migration, penetration and fracture. This product, along with the new Cleaner15™ Mechanical Thrombectomy System, and the recently announced acquisition of Angiotech’s Interventional business, positively positions the company as a significant player in the interventional arena.”

OptionELITE’s enhanced retention anchor pattern provides stability and reduced retrieval force while preventing migration and reducing the risk of penetration. The sturdy apex design has an increased capture zone for ease of snaring. In addition, the new high performance spiral sheath remains the lowest profile IVC filter delivery system available today (6.5Fr OD, 5.0Fr ID) and has been reinforced for improved kink-resistance and pushability.

“I have used Option™ for many years. At Weill Cornell, we had the opportunity to participate in the OptionELITE evaluation and found the device to be just as safe and stable as the Option, with no migrations and significantly easier to retrieve,” saidDavid W. Trost, MD, Associate Professor of Clinical Radiology, Weill Medical College of Cornell University in New York, New York.

Argon Medical will be featuring the OptionELITE IVC Filter at the 38th Annual Scientific Meeting of the Society of Interventional Radiology in New Orleans, Louisiana, April 13 – 18, 2013 and will be offering a hands-on simulator training experience at booth 840.

PE affects an estimated 600,000 to 1,000,000 people in the US and its incidence is increasing annually. PE is the sudden blockage of an artery in the lung (pulmonary artery) typically blood clot (thrombus). Emboli dislodgement can be caused by peripheral vascular disease (PVD), severe deep vein thrombosis (DVT), trauma and prolonged immobilization often following major surgical procedures. PE occurs when these clots break loose and embolize to block pulmonary blood vessels in the lungs. According to clinical research, if left untreated, PE has a mortality rate of 30% and is a leading cause of inpatient deaths in US hospitals.

About Argon

Argon Medical Devices is a global manufacturer of specialty medical products headquartered in Plano, Texas. Argon offers a diverse line of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Critical Care procedures. Its products include the Option™ELITE Retrievable Vena Cava Filter, Cleaner Rotational Thrombectomy Systems, and the UltraStream™ Chronic Dialysis Catheter. The recently announced acquisition of Angiotech’s Interventional business, brings best -in-class products such as BioPince™ Full Core Biopsy Instruments, Skater™ All-Purpose Drainage Systems, and Atrieve Vascular Snare™ Kits, into the Argon product portfolio. Argon Medical Devices is a privately held portfolio company of Roundtable Healthcare Partners, which is committed to providing clinicians with innovative, technology-driven solutions to improve patient outcomes.

About Roundtable

RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the health-care industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified health-care companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

About Rex Medical, LP

Rex Medical, LP, based in Conshohocken, PA, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery and oncology markets. Rex Medical is ISO 13485 certified.

LAKE FOREST, IL, MARCH 25, 2013 — RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Argon Medical Devices, Inc. (“Argon” or the “Company”), entered into a definitive agreement to acquire the Interventional Products Business of Angiotech Pharmaceuticals, Inc. (“Angiotech”). The Interventional Products Business manufactures and markets disposable and re-usable biopsy products for the diagnosis of cancer, drainage catheter products, and vascular interventional products. The transaction is expected to be completed prior to the end of April 2013 subject to customary closing conditions.

The acquisition of the Interventional Products Business bolsters Argon’s existing portfolio of interventional vascular products, adds additional biopsy product lines, and further leverages the Company’s sales force within core call points. As part of the transaction, Argon will also acquire three dedicated manufacturing facilities in Wheeling, IL; Gainesville, FL; and Rochester, NY. Argon currently manufactures its products in facilities in Athens, TX and Singapore.

“The Interventional product franchise is well recognized by hospitals and physicians worldwide,” said Michael J. Hudson, CEO of Argon. “The acquisition of these products strengthens the Argon portfolio and cements our Company’s position as a key player in the Interventional Radiology, Cardiac Catheterization and Vascular Surgery markets.”

The Interventional Products Business was created by RoundTable in 2003 as part of its American Medical Instruments Holdings, Inc. (“AMIH”) investment. The AMIH business was run by Argon’s current management team including: Michael Hudson, Argon’s CEO; Richard Adloff, Argon’s CFO; and George Leondis, Argon’s President. AMIH combined the formerly independent Manan Medical, MD Tech, PBN Medical, and American Medical Instruments into a consolidated operating unit. Angiotech acquired the Interventional Products Business from RoundTable in 2006 as a part of its purchase of AMIH.

“We are extremely excited to own the business again,” added Joseph F. Damico, Founding Partner and Co-Chairman of RoundTable. “Our significant history with this excellent management team in the interventional segment, along with our in-house resources in sales and manufacturing will assist the Argon team in effectively integrating these two businesses to position the combined company for significant growth.”

About RoundTable Healthcare Partners

RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the healthcare industry. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise. RoundTable has established a successful track record of working with owner/founders, family companies, management teams, entrepreneurs and corporate partners who share a vision and believe in the value creation potential of its partnership model. RoundTable currently manages $1.9 billion in capital, including three equity funds totaling $1.5 billion and two subordinated debt funds totaling $400 million. More information about RoundTable Healthcare Partners can be found at www.roundtablehp.com.

About Argon Medical Devices

Founded in 1972, Argon is a global manufacturer of specialty medical products headquartered in Plano, Texas. Argon offers a broad line of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Critical Care procedures. Current products include the Option™ Retrievable Inferior Vena Cava Filter, Cleaner Rotational Thrombectomy System, and UltraStream™ Chronic Dialysis Catheter. Argon also offers a complete line of PICC and midline catheters, endomyocardial biopsy forceps, introducer sheaths, pressure transducers, and other vascular products. The Company’s products are sold globally through a combination of direct sales representatives and premier specialty distributors. For more information on Argon, please visit www.argonmedical.com.

“We are excited to introduce this leading-edge addition to the Cleaner line of devices,” commented George A. Leondis, President of Argon. “The introduction of Cleaner15™ illustrates Argon’s commitment to providing best-in-class technologies that enable clinicians to improve outcomes for patients undergoing mechanical thrombectomy procedures.”

The Cleaner15™ Rotational Thrombectomy System utilizes a 15mm single, sinusoidal wire that allows for safe and effective thrombus removal. The 0.044 wire combined with the increase in torque provides the physician with the power needed for difficult declot cases resulting in reduced procedure time, along with enhanced steerability in tight stenoses and aneurysms. (Cleaner15™ Rotational Thrombectomy System is designed and manufactured by Rex Medical, L.P., Conshohocken, PA).

“The Cleaner15™ technology provides efficiency and robust power in challenging thrombectomy cases. The radial force of the sinusoidal wire engages thrombus and has the ability to expand to 15mm allowing for maceration of thrombus effectively, while maintaining procedural safety. I feel very comfortable using the device in all applications including stents and venous valves without risk of binding,” stated Dr. Mark Goldberg, MD, Medical Director of the Center for Dialysis Access, Oakwood, OH.

Argon Medical will be exhibiting at the 25th Annual International Society of Endovascular Therapy (ISET) Scientific Meeting to be held in Miami, FL from January 19th thru the 23rd at the Fontainebleau Miami Beach.

Nearly 600,000 patients currently undergo treatment in the U.S. for End-Stage Renal Disease (ESRD). In addition, over 300,000 procedures are being performed annually in the U.S. to repair and clear thrombosed hemodialysis access grafts and fistulae. It is estimated that the dialysis patient population will continue to grow at a rate exceeding 6% annually.

About Argon

Founded in 1972, Argon Medical is a global manufacturer of specialty medical products headquartered in Plano, Texas. Argon offers a broad line of medical devices for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Critical Care procedures. Current products include the Option™ Retrievable Inferior Vena Cava Filter, Cleaner Rotational Thrombectomy System, and UltraStream™ Chronic Dialysis Catheter. Argon also offers a complete line of PICC and midline catheters, endomyocardial biopsy forceps, introducer sheaths, pressure transducers, and other vascular products. Our products are sold globally through a combination of direct sales representatives and premier specialty distributors.

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, is pleased to announce that Argon Medical (LiDCO’s partner in Japan) has confirmed that the LiDCOrapid Monitor and associated disposable products have been successfully approved by the Japanese Ministry of Health, Labour and Welfare (MHLW). LiDCO believes that Japan is the second largest market in the world for hemodynamic monitoring with approximately 680,000 high-risk surgical patients per annum who would benefit clinically from improved intraoperative fluid management.

The LiDCO products will be shown at the forthcoming Japanese Anesthetic Society Meeting in Kobe on the 7th – 9th of June.

Dr Terry O’Brien, CEO of LiDCO, commented: “We are delighted that our partner Argon Medical has successfully concluded the approval process in Japan and will be promoting the product in the very near future. Minimally invasive hemodynamic monitoring in Japan has a potential market value of US$285 million per annum. We greatly welcome the substantial market opportunity this presents for LiDCO’s fluid monitoring technology.”

George A. Leondis, President of Argon Medical Devices, Inc added: “We are pleased to have received this most important approval. This next generation technology expands our critical care portfolio, offering clinicians a versatile, new and more effective option in minimally invasive, hemodynamic monitoring.”

“UltraStream provides clinicians with an innovative tool to improve care and quality of life for their patients,” commented George Leondis, President of Argon. “This unique technology broadens our dialysis platform and highlights our commitment to this growing disease state.”

The UltraStream Chronic Hemodialysis catheter is the only Chronic Dialysis catheter available with innovative dual lumen arterial lines and a modified step tip design that allow for high flow rates and ease of insertion, providing the combination of clinician satisfaction and improved patient outcomes. This exclusive step tip design allows for placement, both over the wire, and through a peel-away sheath. The seamless transition from the dilator to the step tip facilitates easier catheter exchanges.

UltraStream catheters are provided in a variety of set configurations to meet physician preferences.

There are currently over 571,000 patients diagnosed and treated for End-Stage Renal Disease, with over 116,000 newly diagnosed patients in 2009.* This 3.5% increase in ESRD is the highest since 2000.

RoundTable Healthcare Partners, based in Lake Forest, IL, is an operating-oriented private equity firm focused exclusively on the health-care industry. The partners of RoundTable have significant experience in managing, operating, acquiring and financing multibillion-dollar diversified health-care companies. RoundTable partners with companies that can benefit from its extensive industry relationships and proven operating and transaction expertise.

About Rex

Rex Medical, LP, based in Conshohocken, PA, is a privately held medical device company specializing in the development, manufacturing and marketing of minimally invasive medical devices targeted towards the cardiovascular, venous access, endosurgery and oncology markets.

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, today announces that it has signed an agreement with Argon Medical Devices, Japan, K.K. (“Argon Medical”) to register with the Japanese Ministry of Health, Labour and Welfare the LiDCOrapid monitor and disposable kit for the Japanese market.

Dr Terry O’Brien,CEOof LiDCO, commented: “We are delighted to sign this agreement with Argon Medical and commence the regulatory approval process for the Japanese market. Minimally invasive hemodynamic monitoring is becoming well established in Japan and the Board believes that the Japanese hemodynamic monitoring high risk surgery market has a potential market value of US$285 million per annum, with reimbursement available. Through our partnership with Argon Medical Devices Japan, LiDCO will be well positioned to capitalize on this.”

George Leondis, President of Argon Medical Devices, Inc added: “We are very pleased to again collaborate with LiDCO. Our partnership on this groundbreaking technology is a significant step forward in the growth of Argon’s Critical Care business in Japan.”

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO’s products facilitate the application of hemodynamic optimization protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimization of patients’ hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO’s computer-based technology, developed at St Thomas’ Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.